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Based on our experience, we believe that Nd:YAG laser should
be considered in patients with multiple glomangiomas where other
treatments may carry more risk or cause greater levels of pain.
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A 70-year-old woman with autoimmune haemolytic anaemia
(IgG1-mediated) had been under several immunosuppressant
agents for 8 years with a satisfactory response until she was
admitted for acute severe haemolytic anaemia. The patient was
(a) (b)
(c) (d)
Figure 1 (a,b) Physical examination
revealed well-deﬁned erythematous
plaques, with a smooth surface, arranged in
a concentric and polycyclic shapes and
located on the posterior surface of the
thighs, hips and glutei. (c,d) Similar plaques
were observed on the extensor surface of
both arms/forearms.
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successfully treated with intravenous rituximab (RTX), four
infusions (500 mg EV). Recurrence occurred 9 months later and
RTX was reintroduced (four infusions). One week after the third
RTX infusion, the patient noticed a well-defined erythematous
plaque on the right arm with burning sensation. After spontane-
ous resolution in 2 weeks, the patient received the fourth RTX
infusion. One week later, an erythematous plaque on the right
arm and forearm appeared, persisting for 6 weeks before dissem-
ination with accompanying burning sensation.
The patient was then referred to a Dermatology appointment,
presenting with bilateral and symmetrically distributed well-
defined erythematous plaques, with a smooth surface, arranged
in a concentric and polycyclic shapes and located on the exten-
sor surface of both arms/forearms and posterior surface of the
thighs, hips and glutei (Fig. 1). No other relevant signs or symp-
toms were present.
The patient had a typical cushingoid phenotype, osteopo-
rosis, hypertension and heart failure and was currently
taking prednisolone 25 mg daily (0.3 mg/kg daily), esomep-
razole, bisoprolol, furosemide, alendronic acid and colecalcif-
erol. No new drug was started on the preceding months.
Malignancies and infections (including borreliosis) were
excluded. Diagnostic criteria for systemic lupus erythematous
were not met. The patient did not recall similar annular
rashes before the use of RTX. A punch biopsy was
performed and histopathological examination revealed an
elastotic and edematous dermis, with a lympho-histiocytic
perivascular inflammatory infiltrate as well as focal erythro-
cyte extravasation. Minor aspects: mild hyperkeratosis and
focal spongiosis.
No further RTX infusions were given and gradual regression
of the dermatosis occurred in 2 weeks. Clinical history and skin
histology were compatible with the deep form of erythema
annulare centrifigum.
Discussion
Erythema annulare centrifugum (EAC) is a variant of figurate
erythema, presenting with erythematous macules and papules
that enlarge slowly by peripheral extension to form ringed, arcu-
ate or polycyclic figures with central clearing. It has been tradi-
tionally divided into superficial and deep forms, the former
presenting with trailing scales on the inside border and the latter
infiltrated plaques with no superficial scale.1,2 After confirming
the diagnosis and excluding common assumed triggers (infec-
tions, malignancy and pregnancy),2 a definite aetiology is still
difficult to prove. EAC can be chronic or self-limiting and
immunosuppressive medications are commonly given.2
Rituximab is a chimeric murine/human monoclonal antibody
directed against the B-cell antigen: CD20. The cutaneous side-
effects of RTX are frequent, but usually not serious.3 They can
be divided into infusion reactions, infections, skin malignancies
and other, including Erythema Multiforme, Stevens–Johnson
Syndrome, Toxic Epidermal Necrolysis, Bullous dermatitis and
Paraneoplastic Pemphigus.4 The onset of the reported reactions
has varied from 1 to 13 weeks following RTX exposure.3
The temporal relationship with RTX administration and a
concomitant autoimmune disease makes the authors speculate
about the importance of immunological disturbance on the
pathogenesis of EAC.
In conclusion
● Erythema annulare centrifugum represents a clinical reac-
tion pattern rather than a specific clinicopathological
entity.1
● To the authors’ knowledge, this is the first reported case of
EAC after RTX therapy.
(a)
(b)
Figure 2 (a,b) Histopathological examination revealed an elas-
totic and oedematous dermis, with a lympho-histiocytic perivas-
cular inﬂammatory inﬁltrate as well as focal erythrocyte
extravasation. Minor aspects: mild hyperkeratosis and focal
spongiosis.
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● Its onset is thought to be immunologically mediated.5
Increasing use of biological agents and subsequent new dis-
coveries from pharmacological immunomodulation may
shed some light on its pathophysiology.
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Secukinumab improves the signs
and symptoms of moderate-
to-severe plaque psoriasis in
subjects with involvement of
hands and/or feet: subanalysis




Psoriasis affecting the hands and/or feet has greater impact on
quality of life than other forms of the disease and is more diffi-
cult-to-treat, as topical and systemic therapies and phototherapy
are often ineffective, difficult to administer, and/or limited by
toxicity effects.1,2 Biologics targeting pro-inflammatory cyto-
kines such as tumour necrosis factor (TNF) and interleukin
(IL)-12/23 have shown efficacy in managing moderate-to-severe
plaque psoriasis3,4 and have also demonstrated efficacy in the
treatment of difficult-to-treat disease, including hand/foot psori-
asis.5–7 Secukinumab (Novartis Pharma AG, Basel, Switzerland)
is a fully human IgG1j anti–IL-17A monoclonal antibody that
selectively suppresses the inflammatory cascade induced by
IL-17A. The efficacy and safety of secukinumab for the treatment
of moderate-to-severe psoriasis has been demonstrated in proof-
of-concept and other phase 2 studies.8–10 In a post hoc analysis
of a multicentre, randomized, double-blind, placebo-controlled,
dose-ranging phase 2 study,9 we evaluated the effects of
secukinumab in a subgroup of subjects with moderate-to-severe
psoriasis involving the hands and/or feet.
A complete description of the design/methods for the primary
study was published previously.9 Subjects (N = 125) were ran-
domized 1 : 1 : 1 : 1 : 1 to four subcutaneous secukinumab
regimens (1 9 25 mg, 3 9 25 mg, 3 9 75 mg, 3 9 150 mg)
or matching placebo at baseline and Weeks 4 and 8. After the
12-week treatment period, subjects entered a 24-week follow-up
period. Subjects ≥18 years with a ≥6-month history of moder-
ate-to-severe psoriasis (psoriasis area and severity index [PASI]
score ≥12, overall body [6-point static] investigator’s global
assessment (IGA) score ≥3, and body surface area involvement
≥10%) were enrolled. Our analysis was conducted on a subgroup
with a baseline hand/foot 5-point static IGA score ≥2 (Table 1).
The palm or sole most seriously affected at baseline was assessed
throughout the study. Whole-body outcomes were assessed
using PASI scores.11 Secukinumab’s efficacy was assessed as the
percentage of subjects achieving an IGA response at Week 12
(those achieving a score of 0 [clear] or 1 [almost clear/minimal]
and a ≥2-point improvement on the 5-point hand/foot IGA scale
compared with baseline). Percentages of subjects achieving PASI
75 (≥75% reduction in PASI score from baseline) and PASI 90
(≥90% reduction from baseline) responses were also evaluated at
Week 12. Comparisons between secukinumab and placebo were
performed using the Cochran–Mantel–Haenszel (CMH) test,
Table 1 Investigator’s global assessment (IGA) rating scale for
hand and foot involvement
Score Short description Detailed description
0 Clear No signs of plaque psoriasis
1 Almost clear/
Minimal
Just perceptible erythema and scaling
2 Mild Light pink erythema with minimal
scaling with or without pustules
3 Moderate Dull, red, clearly distinguishable
erythema with diffuse scaling,
some thickening of the skin, with or
without pustule formation
4 Severe Deep or dark red erythema with clearly
obvious diffuse scaling and thickening
and numerous ﬁssures with or without
pustules
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